drugset
drugset / Trial / NCT03136809

ALS Treatment Extension Study

NCT03136809 ↗

Phase 1/2 Unknown 28 enrolled Collaborative Medicinal Development Pty Limited
NaSingle-groupOpen-labelTreatment

Summary

Treatment extension study for ALS/MND patients who participated in phase 1 study CMD-2016-001, completed assessments following six 28-day cycles of treatment, and whom the Investigator considers would benefit from continued CuATSM treatment.

Timeline

Start
2018-01-18
Primary completion
2022-12-31
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject ATSM COPPER (II) Small molecule — —

Indications

amyotrophic lateral sclerosis